The current landscape of early drug development for patients with sarcoma in the immunotherapy era

Ana Sebio, Breelyn A Wilky, Vicki L. Keedy, Robin L. Jones

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Immunotherapy has changed the treatment paradigm of melanoma and other malignancies. Recently, trials of checkpoint inhibition in sarcomas have been far from outstanding, although specific sarcoma subtypes appear to benefit from these novel therapies. The next steps involve combining immune checkpoint inhibition with classic cancer therapies in order to increase immunogenicity and also potentially complex immunotherapy techniques such as adoptive cell therapy. Currently, numerous clinical trials are exploring different immunotherapies in the sarcomas. Herein, we describe some of the preclinical and clinical data that have laid the groundwork for the use of immunotherapies in sarcomas, as well as the current and future studies that could make immunotherapy a therapeutic option for patients with sarcoma.

Original languageEnglish (US)
Pages (from-to)1197-1211
Number of pages15
JournalFuture Oncology
Volume14
Issue number12
DOIs
StatePublished - May 1 2018

Fingerprint

Sarcoma
Immunotherapy
Pharmaceutical Preparations
Therapeutics
Cell- and Tissue-Based Therapy
Melanoma
Neoplasms
Clinical Trials

Keywords

  • immunotherapy
  • PD-1
  • PD-L1
  • sarcoma
  • treatment
  • trials

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

The current landscape of early drug development for patients with sarcoma in the immunotherapy era. / Sebio, Ana; Wilky, Breelyn A; Keedy, Vicki L.; Jones, Robin L.

In: Future Oncology, Vol. 14, No. 12, 01.05.2018, p. 1197-1211.

Research output: Contribution to journalReview article

Sebio, Ana ; Wilky, Breelyn A ; Keedy, Vicki L. ; Jones, Robin L. / The current landscape of early drug development for patients with sarcoma in the immunotherapy era. In: Future Oncology. 2018 ; Vol. 14, No. 12. pp. 1197-1211.
@article{6cbffd21888d4c49b5e4dff13f2ddd3a,
title = "The current landscape of early drug development for patients with sarcoma in the immunotherapy era",
abstract = "Immunotherapy has changed the treatment paradigm of melanoma and other malignancies. Recently, trials of checkpoint inhibition in sarcomas have been far from outstanding, although specific sarcoma subtypes appear to benefit from these novel therapies. The next steps involve combining immune checkpoint inhibition with classic cancer therapies in order to increase immunogenicity and also potentially complex immunotherapy techniques such as adoptive cell therapy. Currently, numerous clinical trials are exploring different immunotherapies in the sarcomas. Herein, we describe some of the preclinical and clinical data that have laid the groundwork for the use of immunotherapies in sarcomas, as well as the current and future studies that could make immunotherapy a therapeutic option for patients with sarcoma.",
keywords = "immunotherapy, PD-1, PD-L1, sarcoma, treatment, trials",
author = "Ana Sebio and Wilky, {Breelyn A} and Keedy, {Vicki L.} and Jones, {Robin L.}",
year = "2018",
month = "5",
day = "1",
doi = "10.2217/fon-2017-0565",
language = "English (US)",
volume = "14",
pages = "1197--1211",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "12",

}

TY - JOUR

T1 - The current landscape of early drug development for patients with sarcoma in the immunotherapy era

AU - Sebio, Ana

AU - Wilky, Breelyn A

AU - Keedy, Vicki L.

AU - Jones, Robin L.

PY - 2018/5/1

Y1 - 2018/5/1

N2 - Immunotherapy has changed the treatment paradigm of melanoma and other malignancies. Recently, trials of checkpoint inhibition in sarcomas have been far from outstanding, although specific sarcoma subtypes appear to benefit from these novel therapies. The next steps involve combining immune checkpoint inhibition with classic cancer therapies in order to increase immunogenicity and also potentially complex immunotherapy techniques such as adoptive cell therapy. Currently, numerous clinical trials are exploring different immunotherapies in the sarcomas. Herein, we describe some of the preclinical and clinical data that have laid the groundwork for the use of immunotherapies in sarcomas, as well as the current and future studies that could make immunotherapy a therapeutic option for patients with sarcoma.

AB - Immunotherapy has changed the treatment paradigm of melanoma and other malignancies. Recently, trials of checkpoint inhibition in sarcomas have been far from outstanding, although specific sarcoma subtypes appear to benefit from these novel therapies. The next steps involve combining immune checkpoint inhibition with classic cancer therapies in order to increase immunogenicity and also potentially complex immunotherapy techniques such as adoptive cell therapy. Currently, numerous clinical trials are exploring different immunotherapies in the sarcomas. Herein, we describe some of the preclinical and clinical data that have laid the groundwork for the use of immunotherapies in sarcomas, as well as the current and future studies that could make immunotherapy a therapeutic option for patients with sarcoma.

KW - immunotherapy

KW - PD-1

KW - PD-L1

KW - sarcoma

KW - treatment

KW - trials

UR - http://www.scopus.com/inward/record.url?scp=85047542437&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047542437&partnerID=8YFLogxK

U2 - 10.2217/fon-2017-0565

DO - 10.2217/fon-2017-0565

M3 - Review article

C2 - 29699407

AN - SCOPUS:85047542437

VL - 14

SP - 1197

EP - 1211

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 12

ER -